NCT05463679 - Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

March 31, 2027

Conditions

Vascular Ehlers-Danlos Syndrome

Interventions

DRUG

Enzastaurin

500 mg QD orally in the form of four 125 mg tablets with background standard of care

DRUG

Placebo

Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care

Trial Locations (1)

Aytu BioPharma, Englewood